Roman Butler Fullerton & Co. Invests $414,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Roman Butler Fullerton & Co. acquired a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 6,751 shares of the biopharmaceutical company's stock, valued at approximately $414,000.

Several other hedge funds have also recently bought and sold shares of HALO. QRG Capital Management Inc. acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at approximately $281,000. Janney Montgomery Scott LLC grew its holdings in Halozyme Therapeutics by 2.2% in the 1st quarter. Janney Montgomery Scott LLC now owns 294,123 shares of the biopharmaceutical company's stock worth $18,768,000 after buying an additional 6,392 shares in the last quarter. Elevation Point Wealth Partners LLC increased its position in Halozyme Therapeutics by 128.0% in the 1st quarter. Elevation Point Wealth Partners LLC now owns 12,936 shares of the biopharmaceutical company's stock valued at $825,000 after acquiring an additional 7,263 shares during the period. Marshall Financial Group LLC raised its stake in Halozyme Therapeutics by 4.8% during the 1st quarter. Marshall Financial Group LLC now owns 33,545 shares of the biopharmaceutical company's stock valued at $2,141,000 after acquiring an additional 1,548 shares in the last quarter. Finally, Bellecapital International Ltd. acquired a new position in Halozyme Therapeutics during the 1st quarter worth $210,000. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Trading Down 1.5%

NASDAQ HALO opened at $53.11 on Wednesday. The firm's 50 day moving average price is $57.12 and its two-hundred day moving average price is $56.20. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51. The stock has a market cap of $6.54 billion, a price-to-earnings ratio of 14.13, a PEG ratio of 0.36 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The firm had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same quarter in the prior year, the company posted $0.79 earnings per share. The firm's revenue was up 35.2% on a year-over-year basis. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on HALO. Wells Fargo & Company raised their price target on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, May 29th. Benchmark downgraded shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Morgan Stanley cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $73.00 to $62.00 in a report on Wednesday, May 14th. Finally, Leerink Partnrs lowered Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Halozyme Therapeutics presently has an average rating of "Hold" and a consensus target price of $61.90.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 503 shares of the business's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total transaction of $32,217.15. Following the completion of the transaction, the director now owns 33,108 shares of the company's stock, valued at approximately $2,120,567.40. The trade was a 1.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.90% of the stock is currently owned by company insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.